Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors

被引：0

作者：

Diab, Adi ^{[1
]}

Tannir, Nizar ^{[1
]}

Cho, Daniel ^{[2
]}

Papadimitrakopoulou, Vali ^{[1
]}

Bernatchez, Chantale ^{[1
]}

Haymaker, Cara ^{[1
]}

Bentebibel, Salah Eddine ^{[1
]}

Curti, Brendan ^{[3
,4
]}

Wong, Michael ^{[1
]}

Tykodi, Scott ^{[5
,6
]}

Puzanoff, Igor ^{[7
]}

Smalberg, Ira ^{[7
]}

Gergel, Ivan ^{[8
]}

Tagliaferri, Mary ^{[8
]}

Zalevsky, Jonathan ^{[8
]}

Hoch, Ute ^{[8
]}

Aung, Sandra ^{[8
]}

Imperiale, Michael ^{[8
]}

Clemens, Wendy ^{[9
]}

Kluger, Harriet ^{[10
]}

Hurwitz, Michael ^{[10
]}

Hwu, Patrick ^{[1
]}

Sznol, Mario ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] NYU Med Oncol Associates, New York, NY USA

[3] Providence Canc Ctr, Portland, OR USA

[4] Earle A Chiles Res Inst, Portland, OR USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[7] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[8] Nektar Therapeut, San Francisco, CA USA

[9] Bristol Myers Squibb, Lawrence Township, NJ USA

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O20

引用

页数：1

共 50 条

[1] NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
Diab, Adi
Hurwitz, Michael E.
Cho, Daniel C.
Papadimitrakopoulou, Vassiliki
Curti, Brendan D.
Tykodi, Scott S.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Papadimitrakopoulou, V.
Tannir, N.
Bernatchez, C.
Haymaker, C.
Bentebibel, S.
Curti, B.
Wong, M.
Gergel, I.
Tagliaferri, M.
Zalevsky, J.
Hoch, U.
Aung, S.
Imperiale, M.
Cho, D.
Tykodi, S.
Puzanov, I.
Kluger, H.
Hurwitz, M.
Hwu, P.
Sznol, M.
Diab, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2152 - S2152
[3] Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Diab, Adi
Tannir, Nizar M.
Bentebibel, Salah-Eddine
Hwu, Patrick
Papadimitrakopoulou, Vassiliki
Haymaker, Cara
Kluger, Harriet M.
Gettinger, Scott N.
Sznol, Mario
Tykodi, Scott S.
Curti, Brendan D.
Tagliaferri, Mary A.
Zalevsky, Jonathan
Hannah, Alison L.
Hoch, Ute
Aung, Sandra
Fanton, Christie
Rizwan, Ahsan
Iacucci, Ernesto
Liao, Yijie
Bernatchez, Chantale
Hurwitz, Michael E.
Cho, Daniel C.
CANCER DISCOVERY, 2020, 10 (08) : 1158 - 1173
[4] PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
Diab, A.
Hurwitz, M. E.
Tannir, N.
Bernatchez, C.
Haymaker, C.
Bentebibel, S. E.
Curti, B. D.
Wong, M. K. K.
Gergel, I.
Tagliaferri, M.
Zalevsky, J.
Hoch, U.
Aung, S.
Imperiale, M.
Cho, D.
Tykodi, S. S.
Puzanov, I.
Kluger, H.
Hwu, P.
Sznol, M.
ANNALS OF ONCOLOGY, 2017, 28
[5] PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
Diab, A.
Hurwitz, M. E.
Tannir, N.
Bernatchez, C.
Haymaker, C.
Bentebibel, S. E.
Curti, B. D.
Wong, M. K. K.
Gergel, I.
Tagliaferri, M.
Zalevsky, J.
Hoch, U.
Aung, S.
Imperiale, M.
Cho, D.
Tykodi, S. S.
Puzanov, I.
Kluger, H.
Hwu, P.
Sznol, M.
ANNALS OF ONCOLOGY, 2017, 28
[6] Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
Diab, Adi
Marcondes, Mario
Kotzin, Brian
Tagliaferri, Mary Ann
Hoch, Ute
Li, Yunfeng
Cattaruzza, Fiore
Zalevsky, Jonathan
Brohl, Andrew Scott
Brugarolas, James
Bilen, Mehmet Asim
Gupta, Shilpa
Musibay, Evidio Domingo
Conley, Anthony Paul
Borazanci, Erkut Hasan
D'Angelo, Sandra P.
Curti, Brendan D.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[7] A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.
Diab, Adi
Tannir, Nizar M.
Bernatchez, Chantale
Haymaker, Cara L.
Bentebibel, Salah E.
Curti, Brendan D.
Wong, Michael K. K.
Gergel, Ivan
Tagliaferri, Mary Ann
Zalevsky, Jonathan
Hoch, Ute
Aung, Sandra
Imperiale, Michael
Cho, Daniel C.
Tykodi, Scott S.
Puzanov, Igor
Kluger, Harriet M.
Hurwitz, Michael E.
Hwu, Patrick
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
Diab, A.
Marcondes, M.
Tagliaferri, M. A.
Hoch, U.
Zhang, J.
Rubas, W.
Kivimae, S.
Zalevsky, J.
Conley, A. P.
Borazanci, E.
D'Angelo, S. P.
ANNALS OF ONCOLOGY, 2018, 29
[9] A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Bentebibel, Salah-Eddine
Hurwitz, Michael E.
Bernatchez, Chantale
Haymaker, Cara
Hudgens, Courtney W.
Kluger, Harriet M.
Tetzlaff, Michael T.
Tagliaferri, Mary A.
Zalevsky, Jonathan
Hoch, Ute
Fanton, Christie
Aung, Sandra
Hwu, Patrick
Curti, Brendan D.
Tannir, Nizar M.
Sznol, Mario
Diab, Adi
CANCER DISCOVERY, 2019, 9 (06) : 711 - 721
[10] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
Vaena, Daniel A.
Chaves, Jorge
Vogelzang, Nicholas J.
Matrana, Marc Ryan
Gabayan, A. Eli
Riese, Matthew John
Cho, Daniel C.
Tagliaferri, Mary Ann
Zalevsky, Jonathan
Xie, Sunny
Hoch, Ute
Rizwan, Ahsan Naqi
Aung, Sandra
Imperiale, Michael
Schwarz, James K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →